diabetestalk.net

Tradjenta Vs Januvia

Compare Tradjenta Vs Januvia - Iodine.com

Compare Tradjenta Vs Januvia - Iodine.com

Head-to-head comparisons of medication uses, side effects, ratings, and more. Tradjenta (linagliptin) is good add-on medicine for controlling your blood sugar, but may cause body aches. Januvia (sitagliptin) is a good add-on treatment if your blood sugars are not controlled and you don't want to use an injectable medicine. 3.2/ 5 average rating with 143 reviewsforJanuvia Good add-on medicine if your blood sugars are still not controlled Good option if you have bad liver or kidney function. Does not cause hypoglycemia (low blood sugar) when taken by itself. Januvia (sitagliptin) is not linked to worsening heart failure like other medicines in its class. Uses the hormones naturally produced by your body to affect how sugar is processed. It is less likely to cause weight gain and low blood sugar compared to other diabetes medicines. Not first-choice anti-diabetes medicine because it doesn't lower blood sugar levels as much as others. Available as brand only and may be expensive Lowers A1c (average blood sugar over time) by less than 1%. Some people might get frequent cold-like symptoms. Rare but serious side effects include pancreatitis and severe joint pain. Continue reading >>

Linagliptin Versus Sitagliptin In Patients With Type 2 Diabetes Mellitus: A Network Meta-analysis Of Randomized Clinical Trials

Linagliptin Versus Sitagliptin In Patients With Type 2 Diabetes Mellitus: A Network Meta-analysis Of Randomized Clinical Trials

Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials We are experimenting with display styles that make it easier to read articles in PMC. The ePub format uses eBook readers, which have several "ease of reading" features already built in. The ePub format is best viewed in the iBooks reader. You may notice problems with the display of certain parts of an article in other eReaders. Generating an ePub file may take a long time, please be patient. Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials Khosro Keshavarz, Farhad Lotfi, [...], and Shekoufeh Nikfar Diabetes is one of the most common chronic and costly diseases worldwide and type 2 diabetes is the most common type which accounts for about 90% of cases with diabetes. New medication-therapy regimens such as those containing linagliptin alone or in combination with other medications (within the category of DDP-4 inhibitors) must be evaluated in terms of efficacy and compared with other currently used drugs and then enter the medication list of the country. Hence, this study aimed to compare the clinical efficacy of the two drugs, i.e. linagliptin and sitagliptin, in patients with type 2 diabetes. A systematic review was conducted to identify all clinical trials published by 2015 which compared the two drugs in patients with type 2 diabetes. Using keywords such as linagliptin, type 2 diabetes mellitus, sitagliptin and related combinations, we searched databases including Scopus, PubMed, and Web of Science. The quality of the selected studies was evaluated using the Jadad score. Considering primary and secondary outcomes extracted from the reviewed studies, a network meta Continue reading >>

Similarities & Differences Between Tradjenta Vs Januvia

Similarities & Differences Between Tradjenta Vs Januvia

Tradjenta, the brand name of Linagliptin, is an oral diabetes drug that is prescribed to patients with type 2 diabetes. This medication works by regulating the amount of insulin the pancreas produces after eating a meal. Linagliptin can be used alone or in combination with other diabetes drugs to reduce high blood glucose levels in people with type 2 diabetes. The drug used together with exercise, diet, weight control and blood glucose testing. You should not change any of these factors in order to avoid affecting your blood glucose levels. Januvia is the brand name of Sitagliptin , and is used to treat patients with type 2 diabetes. It can be used together with other diabetes drugs, but should not be used to treat type 1 diabetes . This medication is supposed to be taken orally, and can be taken with or without food. Your dosage will vary depending on how you respond to treatment, your medical condition, and kidney function. You should not take this medication if you are in a state of diabetic ketoacidosis or you are allergic to Sitagliptin. Similarities and Differences Between Tradjenta vs Januvia Both Tradjenta and Januvia are oral medications that are used together with an exercise and diet program to control high blood glucose in patients with type 2 diabetes.The medications can be prescribed to patients with type 2 diabetes to help them control their blood glucose levels. Thus, reducing the risk of long-term health problems. However,these medications should not be used to treat patients who are under the age of 18. Bothdrugs belongs to a class of medications known as DPP-4 inhibitors . DPP-4 inhibitors are responsible for blocking the action of an enzyme called DPP-4 that destroys incretins, which reduces blood sugar levels. This helps to reduce high levels of bl Continue reading >>

Januvia And Tradjenta Battle For Dpp-4 Supremacy

Januvia And Tradjenta Battle For Dpp-4 Supremacy

Valentina Gburcik, cardiovascular & metabolic disorders analyst, GlobalData Enrique Conterno, SVP and president, Lilly Diabetes Januvia is facing increased competition in a market space that seems to be getting evermore crowded. The DPP-4 inhibitor from Merck, which was first to market for the treatment of type 2 diabetes, racked up sales of $4 billion in 2012. However, recently released results for the third quarter of 2013 revealed an unexpectedly poor performance for the medicine. The results are being blamed on increased competition in the market, primarily from another Big Pharma titan. Valentina Gburcik, cardiovascular & metabolic disorders analyst for research and consulting firm GlobalData, notes the competition in this space is stronger than ever, with Big Pharma firms launching new therapies into this market with a force designed to sweep away existing medicines, as well as competitors. “As most therapies within one drug class hardly differentiate from each other, and the differences between entire classes are also relatively unimpressive, business strategy behind new products now means more than anything,” notes Gburcik. Much of the increased competition for Januvia is coming from Eli Lilly and Company. The company’s Tradjenta product, the third-to-market DPP-4 inhibitor, continues to perform very strongly in the market, according to Gburcik. “Eli Lilly and BI (Boehringer Ingelheim) have been adopting a different strategy from Merck by working on diversification of the diabetes portfolio, and they will soon market treatments covering every single anti-diabetes drug class,” says Gburcik. “Instead of focusing on brand, Eli Lilly focuses on the most comprehensive coverage of patients’ needs, and this is certainly strengthening its relationship with Continue reading >>

More in diabetes